| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 7.8MM | - |
| Operating Income | -255.1MM | - |
| Operating Expenses | 262.9MM | - |
| Net Income | -229.6MM | - |
| R&D | 217.4MM | - |
| G&A | 45.5MM | - |
| Amortization | 468K | +56% |
| Interest Expense | - | - |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Simultaneous publication and presentation of RMC-6236 chemical structure, preclinical data and case studies during the “KRAS: Broadening the Attack Beyond G12C with Small Molecules and Immuno-Oncology" Session at AACR 2024 in San DiegoREDWOOD CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the publication of a peer-reviewed research p
Two original papers in Nature highlight the discovery and translational implications of RMC-7977, a RAS(ON) multi-selective tri-complex inhibitor that exhibits unprecedented anti-tumor activity in preclinical models of RAS-mutant pancreatic ductal adenocarcinoma (PDAC) First paper demonstrates RMC-7977 successfully targets signaling by both mutant and wild-type forms of RAS to drive potent and durable inhibition of RAS-mutated cancers Second paper highlights translation-focused research with RMC
REDWOOD CITY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be a featured speaker at the 23rd Annual Needham Healthcare Conference and the Stifel Targeted Oncology Forum. Details of the company’s participation are as follows: 23rd Annual Needham
REDWOOD CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the company will deliver multiple presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024 being held April 5-10, 2024, in San Diego, California. Details of the planned presentations are listed below: Revolution Medicines Oral Presentation
Revolution Medicines, Inc. (NASDAQ:RVMD) Q4 2023 Earnings Call Transcript February 26, 2024 Revolution Medicines, Inc. misses on earnings expectations. Reported EPS is $-1.14 EPS, expectations were $-0.86. Revolution Medicines, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day […]
Revolution Medicines ( NASDAQ:RVMD ) Full Year 2023 Results Key Financial Results Revenue: US$11.6m (down 67% from FY...
Q4 2023 Revolution Medicines Inc Earnings Call
Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of -32.56% and 87.63%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Strategic Focus on RAS(ON) Inhibitors as Company Prepares for Pivotal Trials
Revolution Medicines to hold webcast today at 4:30 p.m. Eastern TimeREDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter and full year ended December 31, 2023, and provided an update on corporate progress. The company’s strategic priorities for 2024 are focused on its pioneering RAS(ON) inhibito